Analysts Offer Predictions for PRCT Q1 Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Equities researchers at William Blair issued their Q1 2026 earnings per share estimates for PROCEPT BioRobotics in a report released on Monday, October 28th. William Blair analyst B. Vazquez forecasts that the company will post earnings of ($0.19) per share for the quarter. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.88) per share. William Blair also issued estimates for PROCEPT BioRobotics’ Q2 2026 earnings at $0.20 EPS and Q3 2026 earnings at $0.16 EPS.

PRCT has been the subject of several other research reports. Piper Sandler restated an “overweight” rating and issued a $75.00 price objective on shares of PROCEPT BioRobotics in a report on Tuesday, October 8th. Truist Financial reissued a “buy” rating and issued a $105.00 price target (up from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday. TD Cowen lifted their price objective on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Wells Fargo & Company increased their target price on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Bank of America lifted their price target on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $88.40.

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ PRCT opened at $90.00 on Wednesday. PROCEPT BioRobotics has a 1 year low of $24.91 and a 1 year high of $99.34. The firm has a market cap of $4.67 billion, a P/E ratio of -46.15 and a beta of 1.03. The stock has a fifty day moving average price of $77.20 and a two-hundred day moving average price of $67.91. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.49 and a current ratio of 7.51.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.09. The business had revenue of $58.40 million during the quarter, compared to the consensus estimate of $53.30 million. PROCEPT BioRobotics had a negative net margin of 58.73% and a negative return on equity of 37.85%. During the same quarter in the prior year, the company posted ($0.51) earnings per share. The company’s quarterly revenue was up 66.4% compared to the same quarter last year.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several institutional investors and hedge funds have recently bought and sold shares of PRCT. Blair William & Co. IL acquired a new stake in shares of PROCEPT BioRobotics during the first quarter worth approximately $21,240,000. Chicago Capital LLC acquired a new stake in shares of PROCEPT BioRobotics during the 2nd quarter valued at $14,233,000. Federated Hermes Inc. boosted its stake in shares of PROCEPT BioRobotics by 788.9% during the 2nd quarter. Federated Hermes Inc. now owns 183,420 shares of the company’s stock valued at $11,205,000 after buying an additional 162,785 shares during the period. Transatlantique Private Wealth LLC purchased a new position in shares of PROCEPT BioRobotics during the 2nd quarter valued at $9,164,000. Finally, M&G Plc acquired a new position in shares of PROCEPT BioRobotics in the second quarter worth $8,507,000. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 288,461 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $91.00, for a total value of $26,249,951.00. Following the completion of the transaction, the chief executive officer now directly owns 258,445 shares in the company, valued at $23,518,495. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Reza Zadno sold 288,461 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $91.00, for a total value of $26,249,951.00. Following the completion of the sale, the chief executive officer now owns 258,445 shares in the company, valued at $23,518,495. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Antal Rohit Desai sold 35,220 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $76.12, for a total value of $2,680,946.40. Following the completion of the sale, the director now directly owns 23,963 shares of the company’s stock, valued at approximately $1,824,063.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 468,353 shares of company stock worth $40,196,366. Company insiders own 17.40% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).